

18. Dezember 2017

Platinum-sensitive ovarian cancer: approval of niraparib

On November 16th the European Commission (EC) has approved the new PARP inhibitor Niraparib (trade name Zejula[®]) for the maintenance treatment of women with platinum-sensitive ovarian cancer. The EC approval of ZEJULA marks TESARO's second product approval in Europe this year after the NK1-antagonist Varuby[®] which is an effective antiemetic for cancer patients. Orlando Oliveira, Senior Vice President and General Manager International of TESARO Bio GmbH located in Zug in Switzerland, tells us about the commitment of TESARO for cancer patients and elucidates why the approval of ZEJULA is a milestone for TESARO in Europe and Germany.

Dauer des Videos: 1:19

Orlando Oliveira, Zug Switzerland